AVEO Oncology (AVEO) announced Thursday that Nasdaq halted trading of its common stock this morning, May 2, 2013. The company also stated that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee or ODAC meets today to discuss the New Drug Application or NDA for tivozanib for the treatment of patients with advanced renal cell carcinoma or RCC.
According to the timelines established by the Prescription Drug User Fee Act or PDUFA, the review of the NDA is expected to be complete by July 28, 2013.
The company noted that it will host a conference call today at 4:30 p.m. (ET) to discuss the ODAC panel's review of the tivozanib NDA.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.